Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Gains from Investment Securities (2020 - 2026)

RxSight filings provide 6 years of Gains from Investment Securities readings, the most recent being -$3000.0 for Q4 2025.

  • On a quarterly basis, Gains from Investment Securities rose 70.0% to -$3000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $74000.0, a 3800.0% increase, with the full-year FY2025 number at $6.6 million, up 11.01% from a year prior.
  • Gains from Investment Securities hit -$3000.0 in Q4 2025 for RxSight, down from $6.8 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $6.8 million in Q3 2025 to a low of -$79000.0 in Q4 2022.
  • Median Gains from Investment Securities over the past 5 years was $430926.0 (2023), compared with a mean of $1.9 million.
  • Biggest five-year swings in Gains from Investment Securities: tumbled 175.24% in 2022 and later surged 15891.23% in 2024.
  • RxSight's Gains from Investment Securities stood at $105000.0 in 2021, then tumbled by 175.24% to -$79000.0 in 2022, then soared by 158.23% to $46000.0 in 2023, then plummeted by 121.74% to -$10000.0 in 2024, then skyrocketed by 70.0% to -$3000.0 in 2025.
  • The last three reported values for Gains from Investment Securities were -$3000.0 (Q4 2025), $6.8 million (Q3 2025), and $6.7 million (Q2 2025) per Business Quant data.